Novartis India Limited

Key Details

  • The Board meeting is scheduled to be held on Thursday, July 23, 2026.
  • The primary purpose of the meeting is to consider and approve the Unaudited Financial Results of the Company for the quarter ended June 30, 2026.
  • The disclosure is made pursuant to Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Submission and Authentication

  • The letter was digitally signed and submitted by Chandni Bhupendra Maru, who holds the designation of Company Secretary and Compliance Officer (Membership Number: A60291).
  • The submission was made to BSE Limited on July 07, 2026, at 14:54:38 IST.